PARENTI, Carmela
 Distribuzione geografica
Continente #
NA - Nord America 8.999
AS - Asia 3.527
EU - Europa 3.224
SA - Sud America 576
AF - Africa 544
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 16.886
Nazione #
US - Stati Uniti d'America 8.723
SG - Singapore 1.844
CN - Cina 1.146
IT - Italia 1.037
IE - Irlanda 615
UA - Ucraina 536
BR - Brasile 507
CI - Costa d'Avorio 374
RU - Federazione Russa 354
CA - Canada 237
DE - Germania 188
VN - Vietnam 131
SE - Svezia 105
SN - Senegal 103
GB - Regno Unito 91
KR - Corea 88
IN - India 70
JP - Giappone 57
FR - Francia 46
FI - Finlandia 38
ES - Italia 32
PL - Polonia 32
NL - Olanda 30
BD - Bangladesh 28
MX - Messico 28
ID - Indonesia 27
BE - Belgio 25
AR - Argentina 24
UZ - Uzbekistan 20
ZA - Sudafrica 20
HK - Hong Kong 19
AT - Austria 17
CH - Svizzera 17
TR - Turchia 16
IQ - Iraq 15
CZ - Repubblica Ceca 14
GR - Grecia 11
PK - Pakistan 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
BJ - Benin 10
EC - Ecuador 10
MA - Marocco 8
VE - Venezuela 8
CL - Cile 7
CO - Colombia 7
DZ - Algeria 7
HU - Ungheria 7
IR - Iran 7
LB - Libano 7
EG - Egitto 6
IL - Israele 6
LT - Lituania 6
PE - Perù 6
TH - Thailandia 6
BG - Bulgaria 5
EU - Europa 5
AL - Albania 4
KE - Kenya 4
NG - Nigeria 4
NO - Norvegia 4
PY - Paraguay 4
SA - Arabia Saudita 4
TN - Tunisia 4
AZ - Azerbaigian 3
AO - Angola 2
BB - Barbados 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
NP - Nepal 2
OM - Oman 2
RS - Serbia 2
SV - El Salvador 2
UY - Uruguay 2
AM - Armenia 1
BO - Bolivia 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
HR - Croazia 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
Totale 16.886
Città #
Dallas 1.712
Houston 1.024
Santa Clara 1.012
Singapore 984
Chandler 794
Dublin 611
Jacksonville 513
Chicago 468
Abidjan 374
Ashburn 365
Catania 331
Boardman 289
Nanjing 190
Beijing 177
Hefei 174
Cambridge 173
Lawrence 173
Andover 171
Toronto 160
Los Angeles 119
Dakar 103
Moscow 98
Civitanova Marche 94
Wilmington 94
Seoul 88
San Mateo 87
Bremen 83
Des Moines 71
Council Bluffs 70
Nanchang 65
Buffalo 58
Columbus 52
Shenyang 52
The Dalles 51
São Paulo 50
Tokyo 50
New York 49
Saint Petersburg 46
Jiaxing 42
Ottawa 42
Rome 42
Changsha 40
Ho Chi Minh City 40
Munich 39
Tianjin 38
Hebei 34
Grafing 32
Naples 31
Hanoi 28
Brussels 24
Warsaw 21
Denver 20
Brooklyn 19
Jakarta 19
Seattle 18
Turku 18
Dong Ket 17
Falls Church 17
Pune 17
Rio de Janeiro 17
Atlanta 16
Hong Kong 16
Messina 16
Montreal 16
Jinan 15
Johannesburg 15
Ningbo 15
Norwalk 15
Belo Horizonte 14
San Giovanni la Punta 14
Amsterdam 13
Augusta 13
Helsinki 13
Washington 13
Boston 12
Mascalucia 11
Orem 11
Phoenix 11
Zhengzhou 11
Campinas 10
Cotonou 10
London 10
Milan 10
Paternò 10
San Francisco 10
Stockholm 10
Chennai 9
Kunming 9
Leawood 9
Madrid 9
Poplar 9
Salerno 9
Salvador 9
Ann Arbor 8
Fremont 8
Fuzhou 8
Haiphong 8
Liberty Lake 8
Mumbai 8
Palermo 8
Totale 12.139
Nome #
Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. 439
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 396
NOP RECEPTOR ANTAGONISM IN THE VENTROLATERAL PERIAQUEDUCTAL GRAY ATTENUATES THE DEVELOPMENT OF OPIOID TOLERANCE. 320
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 274
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 203
Involvement of sigma 2 receptor on motor disorder 189
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 173
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 172
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 160
Inhibition of Cx43 mediates protective effects on hypoxic/reoxygenated human neuroblastoma cells 149
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 146
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 143
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 141
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 135
A new sigma ligand, (+/-)-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effect 134
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 131
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 130
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 129
Connexins in the central nervous system: physiological traits and neuroprotective targets 126
CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro 124
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 122
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 121
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 118
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 118
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 116
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 113
Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands 113
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 112
Intercellular communication and ion channels in neuropathic pain chronicization 112
Sigma-2 receptor ligands QSAR model dataset 110
Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization 110
Chronic treatment with fluoxetine induces sex-dependent analgesic effects and modulates HDAC2 and mGlu2 expression in female mice 109
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 108
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 108
Central and peripheral control by endogenous opioid peptides of gastric protection in stressed-rats 107
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 107
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 107
From plant to bench: natural products as source for analgesic drug development. 107
Studio aerobiologico e incidenza di pollinosi nella popolazione acese 105
Effect of supraspinal Nocistatin on nociceptin/OrphaninFQ antagonism of selective opioid analgesia 105
MOR/DOR targeting: an useful strategy in pain management 105
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 102
Apoptotic effects of (±) MRJF4 in prostate cancer cells 102
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 101
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 101
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 101
(+)-Mr200 derivatives: modifications on the amino moiety. In vitro and in vivo pharmacological evaluation 100
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 100
Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia 100
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 99
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 99
Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na+ /Ca2+ exchanger isoform NCX3 in human neuroblastoma SH-SY5Y cells 99
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 97
Multitarget opioid ligands in pain relief: New players in an old game 96
Effect of CCK-8 on analgesia induced by cold-restraint stress in the rat 96
Neuroprotective effect of the new sigma receptor ligands cis-(+) and cis-(–)-PPCC 96
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 96
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 96
Involvement of the Heme-Oxygenase Pathway in the Antiallodynic and Antihyperalgesic Activity of Harpagophytum procumbens in Rats. 95
Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype 95
Wilms’ Tumor Gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line 95
ANTIALLODYNIC AND ANTIHYPERALGESIC EFFECTS OF INTRAPLANTAR NOCISTATIN AND (±)-J 113397 IN INFLAMMATORY PAIN 95
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 94
Central and peripheral involvement of endogenous opioid peptides in gastric protection in stressed rats 94
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 94
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 93
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 92
Preclinical evidence of enhanced analgesic activity of duloxetine complexed with succinyl-β-cyclodextrin: A comparative study with cyclodextrin complexes 92
Effects of dinorphin 1-13 on hyperalgesia induced by interleukin-1bera in the rat 91
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 90
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 90
Repeated activation of delta opiod receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain: A possible correlation with delta opiod receptors-mediated antiallodinic effect. 90
Prevention of stress-induced gastric ulcers by mu- and delta-opioid agonists in the rat. 89
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 89
Wilms' tumor 1 (WT1) protein expression in human developing tissues 88
Progress in the development of more effective and safer analgesics for pain management 88
Antiallodynic and antihyperalgesic effects of intraplantar nocistatin and (+/-)-J113397 in inflammatory pain 87
Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives 87
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 86
Rescue of noradrenergic system as a novel pharmacological strategy in the treatment of chronic pain: Focus on microglia activation 86
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 85
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 85
Dual-target ligands and pain: our experience 84
Effect of centrally administered -B-endorphin on the development of stress-induced gastric ulcers in rats 84
Effects of a Selective Sigma 1 Antagonist Compound on Inflammatory Pain 84
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 83
In-vitro evaluation of a new benzomorphan-based ligand 83
Different in vitro activity of flurbiprofen and its enantimers on human articular cartilage 83
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 82
HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors 81
Pain management: new long-acting opioid ligands 81
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 81
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 80
Evaluation of N-substitution in 6,7-benzomorphan compounds 80
Harpagophytum procumbens extract potentiates morphine antinociception in neuropathic rats. 80
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 79
Stress-induced changes in the thermic effects of cholecystokinin in the rat 79
Idebenone: Novel strategies to improve its systemic and local efficacy 79
Role of the Nrf2/HO-1 axis in bronchopulmonary dysplasia and hyperoxic lung injuries 79
Supraspinal injection of Substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain 78
Totale 11.458
Categoria #
all - tutte 55.628
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.628


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021518 0 0 0 0 0 35 106 8 110 16 170 73
2021/20221.382 163 178 15 38 210 16 186 56 123 23 56 318
2022/20232.419 196 127 46 291 214 378 8 439 512 45 101 62
2023/20241.265 82 218 78 62 68 286 48 76 2 33 218 94
2024/20254.084 67 747 214 236 877 480 196 188 243 321 243 272
2025/20264.588 527 340 1.908 455 1.315 43 0 0 0 0 0 0
Totale 17.328